ABSTRACT Schizophrenia is a prevalent mental disorder that significantly impacts global health, with approximately 1% of the population affected and around 30% of cases classified as treatment‐resistant schizophrenia (TRS). Clozapine is established as the gold standard for TRS management, yet its use is often complicated by potential adverse effects and the necessity for rigorous blood monitoring due to the risk of severe neutropenia. Recent studies have revealed that clozapine not only influences psychiatric symptoms but also alters immune system functioning and cytokine profiles in patients with schizophrenia. This interplay between clozapine treatment and immune‐related biomarkers warrants deeper investigation to elucidate the underlying mechanisms of the disease and to refine therapeutic approaches. Identifying specific biomarkers could enhance clinical decision‐making regarding the initiation of clozapine therapy, allowing for more tailored treatments and improved patient outcomes.
Wei et al. (Mon,) studied this question.